EUPRAXIA PHARMACEUTICALS INC.
EPRX evidence brief
What we can confirm
- Market Cap:
- $529.9M
What it means
What to watch
Prepared research question
What matters most for EPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing EP-104GI, a Diffusphere™-based drug for eosinophilic esophagitis, with Phase 1b/2a data showing durable symptom and tissue responses and an ongoing Phase 2b trial.
Key risk: Phase 2b trial outcome
Market Cap
$529.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing EP-104GI, a Diffusphere™-based drug for eosinophilic esophagitis, with Phase 1b/2a data showing durable symptom and tissue responses and an ongoing Phase 2b trial.
- Cash & equivalents of $80.6M and shareholders' equity of $82.0M as of 2025-12-31 [sec].
- Lead drug candidate EP-104GI targets eosinophilic esophagitis (EoE) using proprietary Diffusphere™ technology for local, controlled drug delivery [news·2026-10-09].
- Phase 1b/2a RESOLVE trial data showed durable symptom and tissue responses out to 52 weeks following a single treatment [news·2025-11-04].
- Phase 2b placebo-controlled portion of the RESOLVE trial is enrolling, with topline data expected by Q3 2026 [news·2025-11-04].
- Cash runway to fund pipeline development and operations into the first half of 2028 [news·2025-11-04].
What works
- EP-104GI demonstrated durability of symptom responses out to 52 weeks in the highest dose cohort, with 66% of patients maintaining clinical remission [news·2026-09-30].
- The company completed an $80.5 million public offering supported by leading life science investors, providing a cash runway into H1 2028 [news·2025-11-04].
- Data from the Phase 1b/2a RESOLVE trial showed improvement in fibrosis and inflammation following a single treatment, suggesting potential for annual dosing [news·2026-08-11][news·2026-09-30].
What to weigh
- The company is still in clinical-stage with no approved products, relying on successful completion of Phase 2b and subsequent trials [news·2026-10-09].
- Phase 2b topline data is not expected until Q3 2026, leaving a period of uncertainty regarding efficacy in the placebo-controlled setting [news·2025-11-04].
- The highest dose cohort (Cohort 9) had only 3 patients, limiting statistical robustness of the 52-week remission data [news·2026-09-30].
From the filings
Quoted directly from source documents.
Durable symptom and tissue responses out to 52 weeks
“Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI”
News · November 4, 2025
Phase 2b topline data expected by Q3 2026
“Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026”
News · November 4, 2025
Cash runway into first half of 2028
“Cash runway to fund pipeline development and operations into the first half of 2028”
News · November 4, 2025
Catalyst timeline
- 2026-09-30 · Phase 2b topline data — Topline data from the placebo-controlled Phase 2b portion of the RESOLVE trial is expected by Q3 2026, which will be a key efficacy readout.
Risks & what to watch (3)›
Key risks
- Phase 2b trial outcome — Topline data from the placebo-controlled Phase 2b portion is not expected until Q3 2026, creating uncertainty about efficacy [news·2025-11-04].
- Small sample size in cohorts — The highest dose cohort (Cohort 9) had only 3 patients, limiting statistical reliability of long-term remission data [news·2026-09-30].
- No approved products yet — Eupraxia is a clinical-stage company with no marketed drugs, relying entirely on pipeline success [news·2026-10-09].
What to watch
- Phase 2b topline data expected by Q3 2026 [news·2025-11-04].
- Presentations at ACG and UEG medical conferences in late 2026 [news·2026-10-09].
- Cash runway into first half of 2028, but any acceleration in spending could shorten it [news·2025-11-04].
Sources: Catalysts · News · Generated October 14, 2026 · How we verify sources →
Run EUPRAXIA PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EUPRAXIA PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Jun 4, 2026)
- 25.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EPRX short interestFrequently asked questions
What is the AI investment thesis for EUPRAXIA PHARMACEUTICALS INC.?
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing EP-104GI, a Diffusphere™-based drug for eosinophilic esophagitis, with Phase 1b/2a data showing durable symptom and tissue responses and an ongoing Phase 2b trial.
Who is the CEO of EUPRAXIA PHARMACEUTICALS INC.?
Dr. James A. Helliwell FRCPC, M.D. is the chief executive officer of EUPRAXIA PHARMACEUTICALS INC. (EPRX).
Where is EUPRAXIA PHARMACEUTICALS INC. headquartered?
EUPRAXIA PHARMACEUTICALS INC. (EPRX) is headquartered in Victoria, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.